ConductScience.org, home

Paper41599141

Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer.

Dmuchowski B and 8 others. Pharmaceutics, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer. Papers, record 41599141. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41599141

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer.
PubMed
Journal
Pharmaceutics
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-01-31
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References202

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137111371Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37111371PubMed
231105877Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer.Oncotarget2019https://conductscience.org/library/papers/31105877PubMed
329443960TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018https://conductscience.org/library/papers/29443960PubMed
437806087Why Treg should be the focus of cancer immunotherapy: The latest thought.Biomed Pharmacother2023https://conductscience.org/library/papers/37806087PubMed
525214542The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.Ann Oncol2015https://conductscience.org/library/papers/25214542PubMed
633002436
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Lancet Oncol2020https://conductscience.org/library/papers/33002436PubMed
732103175Epigenetic therapy inhibits metastases by disrupting premetastatic niches.Nature2020https://conductscience.org/library/papers/32103175PubMed
821436444Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.Science2011https://conductscience.org/library/papers/21436444PubMed
925616355
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Breast Cancer Res Treat2015https://conductscience.org/library/papers/25616355PubMed
1030941308Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy.Front Oncol2019https://conductscience.org/library/papers/30941308PubMed
1131005381The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?Clin Oncol (R Coll Radiol)2019https://conductscience.org/library/papers/31005381PubMed
1232527117Neoadjuvant treatment for HER2-positive breast cancer.Chin Clin Oncol2020https://conductscience.org/library/papers/32527117PubMed
1340281554Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40281554PubMed
1430345906Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.N Engl J Med2018https://conductscience.org/library/papers/30345906PubMed
1537817263Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.Breast Cancer Res2023https://conductscience.org/library/papers/37817263PubMed
1630203045Immunological differences between primary and metastatic breast cancer.Ann Oncol2018https://conductscience.org/library/papers/30203045PubMed
1733588426CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours.Nature2021https://conductscience.org/library/papers/33588426PubMed
1834439387Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment.Cancers (Basel)2021https://conductscience.org/library/papers/34439387PubMed
1928650338IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.J Clin Invest2017https://conductscience.org/library/papers/28650338PubMed
2030217563Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies.Cancer Lett2018https://conductscience.org/library/papers/30217563PubMed

See all 202 referencesDownload CSV of references

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
LAG33902PubTator's text mininghttps://conductscience.org/library/genes/3902NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41599141

GET https://conductscience.org/api/papers/v1/41599141/references?page=2